Mark Ashby

4.2k citations
45 papers · 2.9k · 2 hit papers · h-index 23

Impact in

  • Oncology top 2%
    • Cancer Treatment and Pharmacology
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies
  • Hematology top 2%
    • Platelet Disorders and Treatments

Papers in

    • Hematopoietic Stem Cell Transplantation 11
    • Platelet Disorders and Treatments 7
    • Blood groups and transfusion 4
    • Acute Myeloid Leukemia Research 3
    • Polyomavirus and related diseases 4
    • Colorectal Cancer Treatments and Studies 3

Mark Ashby

44 papers receiving 2.8k citations

Mark Ashby's Hit Papers

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy 2013 · 392 citations
3920+8+16Years since publication2505007501000

Peers

Mark Ashby
Comparison fields: 5 of 128
  • Oncology 1.3k
  • Hematology 428
  • Cardiology and Cardiovascular Medicine 766
  • Genetics 357
  • Immunology and Allergy 166
Replace Rashmi Chugh with:
Rashmi Chugh United States
Mef Nilbert Sweden
Daniel Albo United States
Walter H. Gotlieb Canada
Siegal Sadetzki Israel
Marlies E. J. Reinders Netherlands
R. Lor Randall United States
Noah Federman United States
Patrick Verschueren Belgium
Mark Ashby relative to Rashmi Chugh United States Rashmi Chugh's profile →
Citations per field
00.5×4.3×
Rashmi Chugh · 1×
Citations per year

Countries citing papers authored by Mark Ashby

Since Specialization
Citations

This map shows the geographic impact of Mark Ashby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Ashby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Ashby more than expected).

Fields of papers citing papers by Mark Ashby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Ashby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Ashby. The network helps show where Mark Ashby may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Ashby, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Ashby Line = papers co-authored together Mark Ashby links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Hit paper breakdown →
20021135
2
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Hit paper breakdown →
2013392
3 2009234
4 2003142
5 2000124
6 201094
7 200067
8 199561
9 199654
10 202050
11 199743
12 198942
13 199842
14 201241
15
Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.
198736
16 199730
17 202028
18
Bladder irrigation does not prevent haemorrhagic cystitis in bone marrow transplant recipients.
199128
19 200125
20
Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis.
199825

About Mark Ashby

Mark Ashby is a scholar working on Hematology, Oncology, Pulmonary and Respiratory Medicine, Physiology and Emergency Medical Services, having authored 45 papers that have together received 2.9k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (11 papers), Platelet Disorders and Treatments (7 papers), Central Venous Catheters and Hemodialysis (4 papers), Polyomavirus and related diseases (4 papers), Blood groups and transfusion (4 papers), Acute Myeloid Leukemia Research (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Acute Lymphoblastic Leukemia research (3 papers). The work is most often cited by research in Oncology (1.3k citations), Hematology (428 citations), Cardiology and Cardiovascular Medicine (766 citations), Genetics (357 citations) and Immunology and Allergy (166 citations). Mark Ashby has collaborated with scholars based in United States, Australia and South Korea. Frequent co-authors include Stanford J. Stewart, Mary Kathryn Pierri, Deborah Keefe, Maureen Murphy, Clifford A. Hudis, Andrew D. Seidman, Virginia Paton, Steven Shak, Fairooz F. Kabbinavar and Axel Grothey. Their work appears in journals such as Biology of Blood and Marrow Transplantation, Journal of Allergy and Clinical Immunology, Journal of Intellectual Disability Research, Journal of Vascular and Interventional Radiology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact